 |
|
|
|
April 2007 Cover
|
|
Althhough a regimen containing tipranavir (Aptivus) plus ritonavir (Norvir) is generally effective in patients who are resistant to other protease inhibitors, one concern with this regimen has been its potential liver
toxicity. However, a new study by an international team of researchers has found reason for cautious optimism. Yes, tipranavir plus ritonavir can, and often does, increase liver enzyme levels, the researchers found. However, less
than one percent of patients in the study who received tipranavir plus ritonavir experienced severe adverse liver events related to those high levels, and most patients who developed highly elevated liver enzymes tended to see
a reduction over time. from TheBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
